Picture loading failed.

Anti-SARS-CoV-2 Spike RBD therapeutic antibody (Pre-made Etesevimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Bamlanivimab/etesevimab is a combination of two monoclonal antibodies, bamlanivimab and etesevimab, administered together via intravenous infusion as a treatment for COVID-19. Both types of antibody target the surface spike protein of SARS?CoV?2.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-196-1mg 1mg 3090
GMP-Bios-ab-196-10mg 10mg 21890
GMP-Bios-ab-196-100mg 100mg 148000
GMP-Bios-ab-196-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-SARS-CoV-2 Spike RBD therapeutic antibody (Pre-made Etesevimab biosimilar,Whole mAb)
INN Name Etesevimab
TargetSARS-CoV-2 Spike RBD
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI Structure7c01:CD
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesEli Lilly and Company;Institute of Microbiology of the Chinese Academy of Sciences;Shanghai Junshi Biosciences
Conditions ApprovedCOVID-19
Conditions Activena
Conditions Discontinuedna
Development Techna